Dare Bioscience Inc (DARE) - Total Assets
Based on the latest financial reports, Dare Bioscience Inc (DARE) holds total assets worth $32.47 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Dare Bioscience Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Dare Bioscience Inc - Total Assets Trend (2011–2025)
This chart illustrates how Dare Bioscience Inc's total assets have evolved over time, based on quarterly financial data. See Dare Bioscience Inc shareholders equity for net asset value and shareholders' equity analysis.
Dare Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Dare Bioscience Inc's total assets of $32.47 Million consist of 83.3% current assets and 16.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76094.5% |
| Accounts Receivable | $573.06K | 1.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Dare Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Dare Bioscience Inc (DARE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dare Bioscience Inc's current assets represent 83.3% of total assets in 2025, a decrease from 93.9% in 2011.
- Cash Position: Cash and equivalents constituted 76094.5% of total assets in 2025, up from 91.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 1.8% of total assets.
Dare Bioscience Inc Competitors by Total Assets
Key competitors of Dare Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Dare Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 0.85 | 1.57 |
| Quick Ratio | 1.14 | 0.85 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.38 Million | $-3.16 Million | $3.49 Million |
Dare Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Dare Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.09 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 46.9% |
| Total Assets | $32.47 Million |
| Market Capitalization | $17.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dare Bioscience Inc's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dare Bioscience Inc's assets grew by 46.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dare Bioscience Inc (2011–2025)
The table below shows the annual total assets of Dare Bioscience Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $32.47 Million | +46.94% |
| 2024-12-31 | $22.10 Million | +3.85% |
| 2023-12-31 | $21.28 Million | -51.44% |
| 2022-12-31 | $43.83 Million | -21.47% |
| 2021-12-31 | $55.81 Million | +639.10% |
| 2020-12-31 | $7.55 Million | +1.45% |
| 2019-12-31 | $7.44 Million | -4.91% |
| 2018-12-31 | $7.83 Million | -45.11% |
| 2017-12-31 | $14.26 Million | -62.16% |
| 2016-12-31 | $37.69 Million | -51.82% |
| 2015-12-31 | $78.22 Million | +46.51% |
| 2014-12-31 | $53.39 Million | +682.09% |
| 2013-12-31 | $6.83 Million | -61.34% |
| 2012-12-31 | $17.66 Million | +5.82% |
| 2011-12-31 | $16.69 Million | -- |
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more